Clinical pharmacology of CAR-T cells: Linking cellular pharmacodynamics to pharmacokinetics and antitumor effects.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Biochimica et Biophysica Acta

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.bbcan.2015.12.001PMID 26748354
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 4-1BB Costimulation Ameliorates T Cell Exhaustion Induced by Tonic Signaling of Chimeric Antigen Receptors

  2015cited by this paper
• DAP12-Based Activating Chimeric Antigen Receptor for NK Cell Tumor Immunotherapy

  2015cited by this paper
• T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.

  2015cited by this paper
• Generation of human memory stem T cells after haploidentical T-replete hematopoietic stem cell transplantation.

  2015cited by this paper
• Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma.

  2015cited by this paper
• Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.

  2015cited by this paper
• Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity.

  2015cited by this paper
• Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T-lymphocytes

  2015cited by this paper
• Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia

  2015cited by this paper
• Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies

  2014cited by this paper
• Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15.

  2014cited by this paper
• Chimeric antigen receptor T cells for sustained remissions in leukemia.

  2014cited by this paper
• ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells.

  2014cited by this paper
• Safety of Targeting ROR1 in Primates with Chimeric Antigen Receptor–Modified T Cells

  2014cited by this paper
• Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy.

  2014cited by this paper
• Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.

  2014cited by this paper
• Multifactorial T-cell Hypofunction That Is Reversible Can Limit the Efficacy of Chimeric Antigen Receptor–Transduced Human T cells in Solid Tumors

  2014cited by this paper
• CD3ζ-based chimeric antigen receptors mediate T cell activation via cis- and trans-signalling mechanisms: implications for optimization of receptor structure for adoptive cell therapy

  2014cited by this paper
• CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma.

  2013cited by this paper
• Receptor Affinity and Extracellular Domain Modifications Affect Tumor Recognition by ROR1-Specific Chimeric Antigen Receptor T Cells

  2013cited by this paper
• Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28-OX40 "super-stimulation".

  2013cited by this paper
• Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity.

  2013cited by this paper
• Bispecific T-cells expressing polyclonal repertoire of endogenous γδ T-cell receptors and introduced CD19-specific chimeric antigen receptor.

  2013cited by this paper
• Paths to stemness: building the ultimate antitumour T cell

  2012cited by this paper
• The hallmarks of cancer

  2012cited by this paper
• B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.

  2012cited by this paper
• Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.

  2012cited by this paper
• OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4+ T cells

  2012cited by this paper
• Pro-survival signaling via CD27 costimulation drives effective CAR T-cell therapy

  2012cited by this paper
• Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.

  2011cited by this paper
• Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia.

  2011cited by this paper
• Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential

  2011cited by this paper
• Activation of Wnt Signaling Arrests Effector Differentiation in Human Peripheral and Cord Blood-Derived T Lymphocytes

  2011cited by this paper
• Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma.

  2011cited by this paper
• Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias.

  2011cited by this paper
• A human memory T-cell subset with stem cell-like properties

  2011cited by this paper
• T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia

  2011cited by this paper
• IL-7 receptor expression identifies suicide gene-modified allospecific CD8+ T cells capable of self-renewal and differentiation into antileukemia effectors.

  2011cited by this paper
• Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication.

  2010cited by this paper
• Targeting γδ T lymphocytes for cancer immunotherapy: from novel mechanistic insight to clinical application.

  2010cited by this paper
• Cutting Edge: Mechanical Forces Acting on T Cells Immobilized via the TCR Complex Can Trigger TCR Signaling

  2010cited by this paper
• Plasma levels of IL-7 and IL-15 in the first month after myeloablative BMT are predictive biomarkers of both acute GVHD and relapse

  2010cited by this paper
• T cell activation upon exposure to patient-derived tumor tissue: a functional assay to select patients for adoptive T cell therapy.

  2010cited by this paper
• Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.

  2010cited by this paper
• The Inducible Costimulator (ICOS) Is Critical for the Development of Human TH17 Cells

  2010cited by this paper
• Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc ‘spacer’ domain in the extracellular moiety of chimeric antigen receptors avoids ‘off-target’ activation and unintended initiation of an innate immune response

  2010cited by this paper
• Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans.

  2010cited by this paper
• Construction and molecular characterization of human chimeric T-cell antigen receptors specific for carcinoembryonic antigen.

  2010cited by this paper
• The Optimal Antigen Response of Chimeric Antigen Receptors Harboring the CD3ζ Transmembrane Domain Is Dependent upon Incorporation of the Receptor into the Endogenous TCR/CD3 Complex

  2010cited by this paper
• Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study.

  2009cited by this paper
• Loss of mismatched HLA in leukemia after stem-cell transplantation.

  2009cited by this paper
• Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired.

  2009cited by this paper
• Costimulatory ligand CD70 allows induction of CD8+ T-cell immunity by immature dendritic cells in a vaccination setting.

  2009cited by this paper
• Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo.

  2009cited by this paper
• gammadelta T cells in cancer immunotherapy: current status and future prospects.

  2009cited by this paper
• IL-7 and IL-15 allow the generation of suicide gene-modified alloreactive self-renewing central memory human T lymphocytes.

  2009cited by this paper
• T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model.

  2009cited by this paper
• Peptide-Major Histocompatibility Complex Dimensions Control Proximal Kinase-Phosphatase Balance during T Cell Activation

  2009cited by this paper
• Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates.

  2008cited by this paper
• Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy.

  2008cited by this paper
• Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system.

  2008cited by this paper
• Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells.

  2008cited by this paper
• Unique Cell Surface Expression of Receptor Tyrosine Kinase ROR1 in Human B-Cell Chronic Lymphocytic Leukemia

  2008cited by this paper
• Functions of natural killer cells

  2008cited by this paper
• Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma.

  2007cited by this paper
• T Cell Activation by Antibody-Like Immunoreceptors: The Position of the Binding Epitope within the Target Molecule Determines the Efficiency of Activation of Redirected T Cells1

  2007cited by this paper
• Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study.

  2007cited by this paper
• CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.

  2006cited by this paper
• A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer

  2006cited by this paper
• A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation.

  2006cited by this paper
• Phoenix-ampho outperforms PG13 as retroviral packaging cells to transduce human T cells with tumor-specific receptors: implications for clinical immunogene therapy of cancer

  2006cited by this paper
• 131I-tositumomab therapy as initial treatment for follicular lymphoma.

  2005cited by this paper
• Suicide gene therapy of graft-versus-host disease induced by central memory human T lymphocytes.

  2005cited by this paper
• Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy.

  2005cited by this paper
• Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells

  2005cited by this paper
• Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells.

  2005cited by this paper
• CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2.

  2005cited by this paper
• Evaluation of OX40 Ligand as a Costimulator of Human Antiviral Memory CD8 T Cell Responses: Comparison with B7.1 and 4-1BBL1

  2005cited by this paper
• Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer.

  2005cited by this paper
• Chemotherapy and the war on cancer

  2005cited by this paper
• A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells.

  2005cited by this paper
• Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer

  2005cited by this paper
• The Role of Extracellular Spacer Regions in the Optimal Design of Chimeric Immune Receptors: Evaluation of Four Different scFvs and Antigens

  2005cited by this paper
• Activation of Resting Human Primary T Cells with Chimeric Receptors: Costimulation from CD28, Inducible Costimulator, CD134, and CD137 in Series with Signals from the TCRζ Chain

  2004cited by this paper
• Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia

  2004cited by this paper
• Interleukin‐2 is essential for CD4+CD25+ regulatory T cell function

  2004cited by this paper
• Natural Killer T Cells Infiltrate Neuroblastomas Expressing the Chemokine CCL2

  2004cited by this paper
• Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells

  2003cited by this paper
• Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15

  2003cited by this paper
• T-cell activation by recombinant immunoreceptors: Impact of the intracellular signalling domain on the stability of receptor expression and antigen-specific activation of grafted T cells

  2003cited by this paper
• CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma

  2002cited by this paper
• Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor

  2002cited by this paper
• Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes

  2002cited by this paper
• Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity.

  2002cited by this paper
• Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.

  2002cited by this paper
• CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.

  2002cited by this paper
• Interleukin (IL)-15 and IL-7 Jointly Regulate Homeostatic Proliferation of Memory Phenotype CD8+ Cells but Are Not Required for Memory Phenotype CD4+ Cells

  2002cited by this paper
• T-cell activation by recombinant receptors: CD28 costimulation is required for interleukin 2 secretion and receptor-mediated T-cell proliferation but does not affect receptor-mediated target cell lysis.

  2001cited by this paper
• Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse.

  2001cited by this paper
• CD27 is required for generation and long-term maintenance of T cell immunity

  2000cited by this paper

• Revolutionizing cancer treatment: an in-depth exploration of CAR-T cell therapies

  2024cites this paper
• Chimeric Antigen Receptor T-Cells (CAR T-Cells): An Engineered Targeted Therapy for Treatment of Cancer

  2024cites this paper
• Tisagenlecleucel: CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma

  2023cites this paper
• Reprogramming T cell differentiation and exhaustion in CAR-T cell therapy

  2023cites this paper
• Treatment with Living Drugs: Pharmaceutical Aspects of CAR T Cells

  2022cites this paper
• Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions

  2022cites this paper
• Could CAR-T cell therapy be promising agent in acute lymphoblastic leukemia?

  2022cites this paper
• Clinical Pharmacology Perspectives for Adoptive Cell Therapies in Oncology

  2021cites this paper
• 3D Models of Surrogate Multiple Myeloma Bone Marrow Microenvironments: Insights on Disease Pathophysiology and Patient-Specific Response to Drugs

  2021cites this paper
• Pharmacokinetic and pharmacodynamic studies of CD19 CAR T cell in human leukaemic xenograft models with dual‐modality imaging

  2021cites this paper
• Combination of metabolic intervention and T cell therapy enhances solid tumor immunotherapy

  2020cites this paper
• Urokinase Plasminogen Activator Receptor (uPAR) Targeted Therapy with Switchable Chimeric Antigen Receptor T-Cell (sCAR T-Cell) Potential as Pancreatic Cancer Immunotherapy Agent

  2020cites this paper
• Overhauling CAR T Cells to Improve Efficacy, Safety and Cost

  2020cites this paper
• CAR T Cell Therapy for Hematological Malignancies

  2019cites this paper
• Measurement and Quantitative Characterization of Whole-Body Pharmacokinetics of Exogenously Administered T Cells in Mice

  2019cites this paper
• Targeted Delivery of siRNA Lipoplexes to Cancer Cells Using Macrophage Transient Horizontal Gene Transfer

  2019cites this paper
• Development of a quantitative relationship between CAR-affinity, antigen abundance, tumor cell depletion and CAR-T cell expansion using a multiscale systems PK-PD model

  2019cites this paper
• Use of cord blood derived T-cells in cancer immunotherapy: milestones achieved and future perspectives

  2018cites this paper
• Extracellular NGFR Spacers Allow Efficient Tracking and Enrichment of Fully Functional CAR-T Cells Co-Expressing a Suicide Gene

  2018cites this paper
• The severe cytokine release syndrome in phase I trials of CD19-CAR-T cell therapy: a systematic review

  2018cites this paper
• Chimeric antigen receptor-engineered T-cell therapy for liver cancer.

  2018cites this paper
• CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia

  2018cites this paper
• Cell therapy products: focus on issues with manufacturing and quality control of chimeric antigen receptor T‐cell therapies

  2018cites this paper
• Molecular tumor targeting of gelonin by fusion with F3 peptide

  2017cites this paper
• Un néolymphocyte T pour une thérapie médicamenteuse de demain : « espoir ou réalité »

  2017cites this paper
• Clinical Pharmacological Considerations on CAR-T Cell Therapy for Cancer

  2017cites this paper
• Science Journals — AAAS

  2017cites this paper
• CAR T-cell therapy: Balance of efficacy and safety

  2017cites this paper
• Clodronate Improves Survival of Transplanted Hoxb8 Myeloid Progenitors with Constitutively Active GMCSFR in Immunocompetent Mice

  2017cites this paper
• Enhancement of antitumor activity by using a fully human gene encoding a single-chain fragmented antibody specific for carcinoembryonic antigen

  2017cites this paper
• The role of the immune system in cancer: From mechanisms to clinical applications.

  2016cites this paper